“Head‐to‐head comparison between sirolimus‐eluting and paclitaxel‐eluting stents in patients with complex coronary artery disease: An intravascular ultrasound study”

Abstract

The present study showed reduced neointimal proliferation after sirolimuseluting as compared to paclitaxel-eluting stents in patients with complex coronary artery disease. Both SES and PES were associated with low rate of angiographic restenosis or major adverse cardiovascular events.

Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the “Real World”—Clinical and angiographic results from the China CYPHER Select registry

“…In-stent and in-segment late loss were 0.14 ± 0.39 mm and 0.11 ± 0.40 mm, and in-stent and in-segment binary restenosis rates were 4.8% and 9.6%, respectively. Although high-risk patients and more complex lesions were included, the results are comparable with those reported in randomized trials [1][2][3][4][5][6][7][8][9][10][11].…”

“…This post-marketing surveillance real world registry reproduces the safety and the effectiveness of CYPHER on significantly reducing restenosis as revealed by randomized clinical trials [1][2][3][4][5][6][7][8][9][10][11]. As the first registry study of CYPHER Select SES, the results also confirm that CYPHER Select SES has similar efficacy on reducing restenosis and similar safety features with CYPHER SES.…”

“…In this registry, one-year clinical follow-up was completed in 98.2% of enrolled patients, and MACE rate at 12 months was 6.51%. Incidences of cardiac death, acute MI, TLR and TVR at 12 months were 1.11%, 1.20%, 5.14% and 5.74%, respectively, which resemble those seen in previous studies [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Angiographic follow-up was obtained in 68.3% (418) of the lesions treated by CYPHER Select SES.…”

“…The CYPHER™ Sirolimus-eluting stent (SES) significantly decreases neointimal proliferation, leading to a striking reduction in clinical and angiographic restenosis rates in both randomized clinical trials [1][2][3][4][5][6][7][8][9][10][11] and real world registries [12][13][14][15][16].…”

Fundamento e desenho do teste randomizado PAINT

“…Many previous randomized studies have compared paclitaxel-and sirolimus-eluting stents [15][16][17][18][19][20][21][22][23][24][25] . However, in addition to the drug, the stents used in those studies differed in all other characteristics (coating and platform), which consequently prevented a more conclusive evaluation of the effects of the drugs themselves.…”